Pan Baoyue, Zheng Xiaojing, Huang Yongwen, Wei Wei, Xu Shije, Chen Siyu, Yin Jiaxin, Zhang Yu, Li Jundong, Zheng Min
Department of Gynecology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, P. R. China.
Department of Gynecology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510060, China.
J Ovarian Res. 2025 Aug 7;18(1):175. doi: 10.1186/s13048-025-01755-7.
The prognostic factors associated with recurrent platinum-resistant ovarian cancer treated with immune checkpoint inhibitor (ICI) therapy need to be identified.
We retrospectively analyzed the efficacy of ICI therapy in patients with recurrent platinum-resistant ovarian cancer at our center. The number of CD8 + T cells and the expression of PD-L1 were assessed using immunohistochemical assays. A multi-analyte flow assay was used to detect the concentrations of 13 inflammatory cytokines. Both univariate and multivariate models were constructed using pretreatment clinical variables and cytokines.
We included 71 patients with recurrent platinum-resistant ovarian cancer treated with at least two cycles of anti-programmed cell death 1 (PD-1); the objective response rate was 36.62%, and the disease control rate was 78.87%. Elevated levels of interferon-alpha 2 (IFN-α2), IL-1β, and IL-12p70 in serum were associated with improved overall survival. Higher levels of monocyte chemoattractant protein 1 (MCP-1) correlated with longer overall survival and progression free survival. According to the results of the multivariate analysis, a high level of C-reactive protein (CRP) (> 10) independently predicted overall survival. Age, low-density lipoprotein cholesterol (LDL-C), tumor necrosis factor-alpha (TNF-α), and MCP-1 were independently associated with progression-free survival. Chemotherapy containing platinum after immunotherapy progression achieved a partial response rate of 55.55%.
The results of ICI combination therapy have demonstrated a response rate of over one third. Peripheral blood markers, such as cytokines, could potentially serve as predictors of immunotherapy efficacy in platinum-resistant ovarian cancer patients.
Not applicable.
需要确定与接受免疫检查点抑制剂（ICI）治疗的铂耐药复发性卵巢癌相关的预后因素。
我们回顾性分析了我院中心ICI治疗铂耐药复发性卵巢癌患者的疗效。采用免疫组化法评估CD8 + T细胞数量和PD-L1表达。使用多分析物流式细胞术检测13种炎性细胞因子的浓度。使用治疗前临床变量和细胞因子构建单变量和多变量模型。
我们纳入了71例接受至少两个周期抗程序性细胞死亡蛋白1（PD-1）治疗的铂耐药复发性卵巢癌患者；客观缓解率为36.62%，疾病控制率为78.87%。血清中干扰素-α2（IFN-α2）、IL-1β和IL-12p70水平升高与总生存期改善相关。单核细胞趋化蛋白1（MCP-1）水平较高与较长的总生存期和无进展生存期相关。根据多变量分析结果，高水平的C反应蛋白（CRP）（>10）独立预测总生存期。年龄、低密度脂蛋白胆固醇（LDL-C）、肿瘤坏死因子-α（TNF-α）和MCP-1与无进展生存期独立相关。免疫治疗进展后含铂化疗的部分缓解率为55.55%。
ICI联合治疗结果显示缓解率超过三分之一。外周血标志物，如细胞因子，可能作为铂耐药卵巢癌患者免疫治疗疗效的预测指标。
不适用。
